Cargando…

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

The advent of tau-targeted positron emission tomography tracers such as flortaucipir ((18)F-AV-1451, also known as (18)F-T807) have made it possible to investigate the sequence of development of tau and amyloid-β in relationship to age, and to the development of cognitive impairment due to Alzheimer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pontecorvo, Michael J., Devous Sr, Michael D., Navitsky, Michael, Lu, Ming, Salloway, Stephen, Schaerf, Frederick W., Jennings, Danna, Arora, Anupa K., McGeehan, Anne, Lim, Nathaniel C., Xiong, Hui, Joshi, Abhinay D., Siderowf, Andrew, Mintun, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382945/ https://www.ncbi.nlm.nih.gov/pubmed/28077397 http://dx.doi.org/10.1093/brain/aww334

Ejemplares similares

A multicentre longitudinal study of flortaucipir ((18)F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
por: Pontecorvo, Michael J, et al.
Publicado: (2019)

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
por: Pontecorvo, Michael J., et al.
Publicado: (2020)

Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression
por: Kotari, Vikas, et al.
Publicado: (2023)

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials
por: Lu, Ming, et al.
Publicado: (2021)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
por: Shcherbinin, Sergey, et al.
Publicado: (2023)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

Flortaucipir (tau) PET in LGI1 antibody encephalitis
por: Day, Gregory S., et al.
Publicado: (2021)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
por: Costoya-Sánchez, Alejandro, et al.
Publicado: (2023)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline
por: Toledo, Jon B., et al.
Publicado: (2022)

Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
por: Makaretz, Sara J, et al.
Publicado: (2018)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease
por: Pontecorvo, Michael J, et al.
Publicado: (2011)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [(18)F]flortaucipir study
por: O’Connor, Antoinette, et al.
Publicado: (2023)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [(18)F]Flortaucipir PET
por: Risacher, Shannon L., et al.
Publicado: (2018)

Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET
por: Hong, Jimin, et al.
Publicado: (2022)

Cryo-EM Structures of Chronic Traumatic Encephalopathy Tau Filaments with PET Ligand Flortaucipir
por: Shi, Yang, et al.
Publicado: (2023)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
por: Tian, Mei, et al.
Publicado: (2022)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Topographic staging of tau positron emission tomography images
por: Schwarz, Adam J., et al.
Publicado: (2018)

Monoamine oxidase binding not expected to significantly affect [(18)F]flortaucipir PET interpretation
por: Wright, Justin P., et al.
Publicado: (2022)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players
por: Alosco, Michael L., et al.
Publicado: (2022)

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
por: Josephs, Keith A., et al.
Publicado: (2020)

Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual
por: Schwarz, Christopher G., et al.
Publicado: (2022)

Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [(18)F]-APN-1607 Study
por: Zhang, Huiwei, et al.
Publicado: (2021)

Deep learning application for the classification of Alzheimer’s disease using (18)F-flortaucipir (AV-1451) tau positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

An Optoelectronics-Based Compressive Force Sensor with Scalable Sensitivity
por: Pennel, Zachary, et al.
Publicado: (2023)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
por: Whitwell, Jennifer L., et al.
Publicado: (2019)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pk699q426ckbc1k661pvbh2l6c